Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 212

1.

Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer.

du Bois A, Floquet A, Kim JW, Rau J, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.

J Clin Oncol. 2014 Sep 15. pii: JCO.2014.55.7348. [Epub ahead of print]

PMID:
25225436
[PubMed - as supplied by publisher]
2.

A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.

Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E.

Ann Oncol. 2014 Sep 10. pii: mdu392. [Epub ahead of print]

PMID:
25210017
[PubMed - as supplied by publisher]
3.

High-grade undifferentiated sarcomas of the uterus: diagnosis, outcomes, and new treatment approaches.

Philip CA, Pautier P, Duffaud F, Ray-Coquard I.

Curr Oncol Rep. 2014 Oct;16(10):405. doi: 10.1007/s11912-014-0405-1.

PMID:
25123078
[PubMed - in process]
4.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial.

Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.

Ann Oncol. 2014 Sep;25(9):1762-9. doi: 10.1093/annonc/mdu237. Epub 2014 Jul 25.

PMID:
25122671
[PubMed - in process]
Free PMC Article
5.

Guidelines for time-to-event endpoint definitions in sarcomas and gastro-intestinal stromal tumors (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).

Bellera CA, Penel N, Ouali M, Bonvalot S, Casalli PG, Nielsen OS, Delannes M, Litière S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le Péchoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijder S, Stoeckle E, Van Glabbeke M, Woll P, Gourgou-Bourgade S, Mathoulin-Pélissier S.

Ann Oncol. 2014 Jul 28. pii: mdu360. [Epub ahead of print] Review.

PMID:
25070543
[PubMed - as supplied by publisher]
6.

Gynecological Cancer InterGroup Consensus Review for Endometrial Stromal Sarcoma.

Amant F, Floquet A, Friedlander M, Kristensen G, Mahner S, Nam EJ, Powell MA, Ray-Coquard I, Siddiqui N, Sykes P, Westermann AM, Seddon B.

Int J Gynecol Cancer. 2014 Sep 3. [Epub ahead of print]

PMID:
25033257
[PubMed - as supplied by publisher]
7.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.

PMID:
24950985
[PubMed - indexed for MEDLINE]
8.

Novel approaches to improve the treatment of rare gynecologic cancers: research opportunities and challenges.

Ledermann JA, Ray-Coquard I.

Am Soc Clin Oncol Educ Book. 2014:e282-6. doi: 10.14694/EdBook_AM.2014.34.e282.

PMID:
24857114
[PubMed - in process]
Free Article
9.

The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.

Cassier PA, Floquet A, Penel N, Derbel O, Bui N'guyen B, Guastalla JP, Pissaloux D, Treilleux I, Saba CE, Blay JY, Ray-Coquard I.

Ann Oncol. 2014 May;25(5):1074-5. doi: 10.1093/annonc/mdu045. Epub 2014 Mar 20. No abstract available.

PMID:
24651409
[PubMed - in process]
10.

Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.

J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.

PMID:
24637997
[PubMed - indexed for MEDLINE]
11.

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R.

Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21.

PMID:
24563479
[PubMed - in process]
12.

[To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region].

Fayet Y, Chasles V, Ducimetière F, Collard O, Berger C, Meeus P, Ranchère-Vince D, Thiesse P, Sunyach MP, Marec-Bérard P, Poncet L, Cousin P, Blay JY, Ray-Coquard I.

Bull Cancer. 2014 Feb;101(2):127-36. doi: 10.1684/bdc.2014.1891. French.

PMID:
24556026
[PubMed - indexed for MEDLINE]
13.

Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group.

Toulmonde M, Bonvalot S, Ray-Coquard I, Stoeckle E, Riou O, Isambert N, Bompas E, Penel N, Delcambre-Lair C, Saada E, Lecesne A, Le Péchoux C, Blay JY, Piperno-Neumann S, Chevreau C, Bay JO, Brouste V, Terrier P, Ranchère-Vince D, Neuville A, Italiano A; French Sarcoma Group.

Ann Oncol. 2014 Mar;25(3):730-4. doi: 10.1093/annonc/mdt576. Epub 2014 Feb 3.

PMID:
24496921
[PubMed - in process]
14.

The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?

Blay JY, Derbel O, Ray-Coquard I.

Pathology. 2014 Feb;46(2):121-5. doi: 10.1097/PAT.0000000000000052. Review.

PMID:
24378393
[PubMed - indexed for MEDLINE]
15.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.

J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.

PMID:
24366937
[PubMed - indexed for MEDLINE]
16.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

Poveda A, Ray-Coquard I, Romero I, Lopez-Guerrero JA, Colombo N.

Cancer Treat Rev. 2014 Apr;40(3):366-75. doi: 10.1016/j.ctrv.2013.08.001. Epub 2013 Aug 8. Review.

PMID:
24296108
[PubMed - indexed for MEDLINE]
Free Article
17.

Biology of ovarian cancer and trabectedin mechanism of action.

Ray-Coquard I.

Future Oncol. 2013 Dec;9(12 Suppl):11-7. doi: 10.2217/fon.13.199. Review.

PMID:
24195525
[PubMed - indexed for MEDLINE]
18.

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.

Penel N, Ray-Coquard I, Bal-Mahieu C, Chevreau C, Le Cesne A, Italiano A, Bompas E, Clisant S, Baldeyrou B, Lansiaux A, Robin YM, Bay JO, Piperno-Neumann S, Blay JY, Fournier C.

Target Oncol. 2014 Sep;9(3):273-7. doi: 10.1007/s11523-013-0299-0. Epub 2013 Nov 12.

PMID:
24218035
[PubMed - in process]
19.

Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.

Gelderblom H, Blay JY, Seddon BM, Leahy M, Ray-Coquard I, Sleijfer S, Kerst JM, Rutkowski P, Bauer S, Ouali M, Marreaud S, van der Straaten RJ, Guchelaar HJ, Weitman SD, Hogendoorn PC, Hohenberger P.

Eur J Cancer. 2014 Jan;50(2):388-96. doi: 10.1016/j.ejca.2013.10.002. Epub 2013 Nov 8.

PMID:
24215845
[PubMed - indexed for MEDLINE]
20.

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network.

Maillet D, Goulvent T, Rimokh R, Vacher-Lavenu MC, Pautier P, Alexandre J, Pujade-Laurraine E, Devouassoux-Shisheboran M, Treilleux I, Ray-Coquard I, Savina A.

Gynecol Oncol. 2014 Jan;132(1):181-7. doi: 10.1016/j.ygyno.2013.10.013. Epub 2013 Oct 22.

PMID:
24157616
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk